{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T19:39:00Z","timestamp":1772221140084,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.prrv.2023.06.004","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T13:09:09Z","timestamp":1689253749000},"page":"65-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Evaluation of the therapeutic efficacy and tolerability of current drug treatments on the clinical outcomes of paediatric spinal muscular atrophy type 1: A systematic review"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2183-6830","authenticated-orcid":false,"given":"Anmar","family":"Al-Taie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayg\u00fcl","family":"K\u00f6seo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prrv.2023.06.004_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D'Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"5-6","key":"10.1016\/j.prrv.2023.06.004_b0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA Consortium Meeting (26\u201328 June 1992, Bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.prrv.2023.06.004_b0015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mus.27358","article-title":"Selecting disease-modifying medications in 5q spinal muscular atrophy","volume":"64","author":"Cartwright","year":"2021","journal-title":"Muscle Nerve"},{"issue":"9","key":"10.1016\/j.prrv.2023.06.004_b0020","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1177\/088307380201700915","article-title":"Severe spinal muscular atrophy variant associated with congenital bone fractures","volume":"17","author":"Felderhoff-Mueser","year":"2002","journal-title":"J Child Neurol"},{"issue":"4","key":"10.1016\/j.prrv.2023.06.004_b0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1183\/20734735.012716","article-title":"Physiology of respiratory disturbances in muscular dystrophies","volume":"12","author":"Lo Mauro","year":"2016","journal-title":"Breathe (Sheff)"},{"issue":"7","key":"10.1016\/j.prrv.2023.06.004_b0030","doi-asserted-by":"crossref","first-page":"7S29","DOI":"10.1016\/S0929-693X(20)30274-8","article-title":"Respiratory management of children with spinal muscular atrophy (SMA)","volume":"27","author":"Fauroux","year":"2020","journal-title":"Arch Pediatr"},{"issue":"5","key":"10.1016\/j.prrv.2023.06.004_b0035","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","article-title":"Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1","volume":"36","author":"Dabbous","year":"2019","journal-title":"Adv Ther"},{"issue":"9","key":"10.1016\/j.prrv.2023.06.004_b0040","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.prrv.2023.06.004_b0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.prrv.2023.06.004_b0050","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease."},{"key":"10.1016\/j.prrv.2023.06.004_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"issue":"14","key":"10.1016\/j.prrv.2023.06.004_b0060","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study","volume":"91","author":"Aragon-Gawinska","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.prrv.2023.06.004_b0065","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al\u2010Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2023.06.004_b0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","article-title":"Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen","volume":"219","author":"Sansone","year":"2020","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.prrv.2023.06.004_b0075","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.prrv.2023.06.004_b0080","first-page":"54","article-title":"Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-Year single centre Australian experience","volume":"39","author":"Chen","year":"2021","journal-title":"Paediatr Respir Rev"},{"issue":"4","key":"10.1016\/j.prrv.2023.06.004_b0085","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.prrv.2023.06.004_b0090","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JND-200533","article-title":"Clinical outcomes in patients with spinal muscular atrophy type 1 treated with nusinersen","volume":"8","author":"de Holanda","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"7","key":"10.1016\/j.prrv.2023.06.004_b0095","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.prrv.2023.06.004_b0100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/thoraxjnl-2020-216564","article-title":"Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1\u20133","volume":"77","author":"Chacko","year":"2022","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.prrv.2023.06.004_b0105","doi-asserted-by":"crossref","first-page":"e15175","DOI":"10.1111\/ped.15175","article-title":"Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen","volume":"64","author":"Ergenekon","year":"2022","journal-title":"Pediatr Int"},{"issue":"3","key":"10.1016\/j.prrv.2023.06.004_b0110","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ppul.25795","article-title":"Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients","volume":"57","author":"Lavie","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"10.1016\/j.prrv.2023.06.004_b0115","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.prrv.2023.06.004_b0120","article-title":"Nusinersen treatment of spinal muscular atrophy - a systematic review","volume":"67","author":"Albrechtsen","year":"2020","journal-title":"Dan Med J"},{"issue":"4","key":"10.1016\/j.prrv.2023.06.004_b0125","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40271-020-00415-w","article-title":"The whole game is changing and you've got hope: Australian perspectives on treatment decision making in spinal muscular atrophy","volume":"13","author":"Farrar","year":"2020","journal-title":"Patient"},{"issue":"4","key":"10.1016\/j.prrv.2023.06.004_b0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pediatrneurol.2015.06.002","article-title":"Delay in diagnosis of spinal muscular atrophy: a systematic literature review","volume":"53","author":"Lin","year":"2015","journal-title":"Pediatr Neurol"},{"issue":"5","key":"10.1016\/j.prrv.2023.06.004_b0135","first-page":"437","article-title":"Onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"26","author":"Naveed","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.prrv.2023.06.004_b0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40263-022-00910-8","article-title":"Risdiplam: A review in spinal muscular atrophy","volume":"36","author":"Paik","year":"2022","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.prrv.2023.06.004_b0145","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2023.06.004_b0150","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J Pediatr"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054223000404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054223000404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:37:02Z","timestamp":1761507422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054223000404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":30,"alternative-id":["S1526054223000404"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2023.06.004","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the therapeutic efficacy and tolerability of current drug treatments on the clinical outcomes of paediatric spinal muscular atrophy type 1: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2023.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}